Rubraca has been authorized as a monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary
MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization. Ipsen research & development executive vice
OliX CEO Dong-ki Lee said: "The approval of this CTA marks an important milestone for OliX's RNAi therapeutic development, by demonstrating that OliX has met and qualified against the
Under the terms of the agreement, CENTOGENE will collaborate with Aldeyra to globally identify patients with Sjögren-Larsson Syndrome (SLS) and to understand the clinical spectrum of this disease.
The study is a combined Phase I and II study in approximately 40 patients to be conducted at specialist centres at the University of California, San Francisco and
The agreement outlines the legal terms under which Beactica and Sanofi collaborate on the characterization of interactions between novel therapeutics and their target proteins. As part of the
Zessly is approved for use in all indications of the reference medicine including rheumatoid arthritis, adult Crohn's disease, pediatric Crohn's disease, adult ulcerative colitis, pediatric ulcerative colitis, ankylosing spondylitis,
Built on the heritage of the market-leading Zetasizer Nano range, and already the proud recipients of a Red Dot 2018 design award, these new flagship instruments deliver significant
The CRL is consistent with the preliminary feedback Cosmo announced on May 9, 2018, stating that the FDA identified unspecified deficiencies that preclude the continuation of the discussion
The company received series A funding under the round led by Oxford Sciences Innovation (OSI), and the participants include Neptune, RT Ventures, GT Healthcare, Tanarra, Fushia and personal
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.